phosphor akt (Proteintech)
Structured Review
Phosphor Akt, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 555 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phosphor+akt/Phospho-AKT1+(Ser473)+Antibody/pm41483432-76-75-99
Average 96 stars, based on 555 article reviews
Images
Related Articles
Luminescence Assay:Article Title: Design, synthesis and biological evaluation of aminopyrimidine derivatives bearing dihydroquinoxalinone as novel EGFRL858R/T790M kinase inhibitors against non-small-cell lung cancer Article Snippet: .. Materials RPMI-1640 medium (ATCC, Rockville, MD, USA, 30-2001), MEM medium (Gibco, Invitrogen Corporation, NY, USA, 11095080), penicillin and streptomycin (Sigma, St. Louis, MO, USA), L-alany-L-glutamine (Zhongqiaoxinzhou Biotech, China, CSP004), sodium pyrurate (Sigma, USA, S9133), Kinase substrate 22 (GL, China, 112393), CCK8 (Beyotime, Shanghai, China), 96- well plates (Biosahrp, BS-MP-96W), CellTiter-Glo luminescent assay (Promega-G7573, USA), Osimertinib (MedChemExpress, Shanghai, China), FITC-conjugated Annexin V (KeyGEN Biotech, NanJing, China, KGA108), PMSF (Solon, OH, USA), NC membranes (Millipore, Schwalbach, Germany), phosphor-EGFR (CST, Tyr1068, #3777T), EGFR (AB clonal, #A11351), other:Article Title: Forkhead Box q1 promotes invasion and metastasis in colorectal cancer by activating the epidermal growth factor receptor pathway. Article Snippet: Protein extracts were isolated from 106 treated cells using mammalian cell lysis reagent containing protease inhibitor cocktail (Sigma–Aldrich, St. Louis, MO, United States) and phosphatase inhibitors (Roche, United States) following the manufacturer’s directions. Blocking Assay:Article Title: Design, synthesis and biological evaluation of aminopyrimidine derivatives bearing dihydroquinoxalinone as novel EGFRL858R/T790M kinase inhibitors against non-small-cell lung cancer Article Snippet: .. After blocking in 5% non-fat dried milk in TBS, membranes were incubated with primary antibodies against phosphor-EGFR (CST, Tyr1068, #3777T), EGFR (AB clonal, #A11351), Article Title: Exploration of novel dihydroquinoxalinone derivatives as EGFR L858R/T790M tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer. Article Snippet: To overcome or delay the drug-resistance of first-generation epidermal growth factor receptor (EGFR) kinase inhibitors and non-selectivity toxicity mediated by second-generation inhibitors, splicing principle was employed to design and synthesize a series of Osimertinib derivatives containing dihydroquinoxalinone (8–30) as the novel third-generation inhibitors against double mutant L858R/T790M in EGFR.. Among them, compound 29 showed excellent kinase inhibitory activity against EGFRL858R/T790M with an IC50 value of 0.55 ± 0.02 nM and potent anti-proliferative activity against H1975 cells with an IC50 value of 5.88 ± 0.07 nM.. Moreover, the strong downregulation effect of EGFR-mediated signaling pathways and the promotion of apoptosis in H1975 cells confirmed its potent antitumor activities. Incubation:Article Title: Design, synthesis and biological evaluation of aminopyrimidine derivatives bearing dihydroquinoxalinone as novel EGFRL858R/T790M kinase inhibitors against non-small-cell lung cancer Article Snippet: .. After blocking in 5% non-fat dried milk in TBS, membranes were incubated with primary antibodies against phosphor-EGFR (CST, Tyr1068, #3777T), EGFR (AB clonal, #A11351), Article Title: Exploration of novel dihydroquinoxalinone derivatives as EGFR L858R/T790M tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer. Article Snippet: To overcome or delay the drug-resistance of first-generation epidermal growth factor receptor (EGFR) kinase inhibitors and non-selectivity toxicity mediated by second-generation inhibitors, splicing principle was employed to design and synthesize a series of Osimertinib derivatives containing dihydroquinoxalinone (8–30) as the novel third-generation inhibitors against double mutant L858R/T790M in EGFR.. Among them, compound 29 showed excellent kinase inhibitory activity against EGFRL858R/T790M with an IC50 value of 0.55 ± 0.02 nM and potent anti-proliferative activity against H1975 cells with an IC50 value of 5.88 ± 0.07 nM.. Moreover, the strong downregulation effect of EGFR-mediated signaling pathways and the promotion of apoptosis in H1975 cells confirmed its potent antitumor activities. Article Title: Design, synthesis and biological evaluation of aminopyrimidine derivatives bearing dihydroquinoxalinone as novel EGFRL858R/T790M kinase inhibitors against non-small-cell lung cancer Article Snippet: After the protein concentrations were determined by a BCA Protein Assay Kit (Thermo Fisher Scientific, Rockford, Illinois, USA), the protein extracts were reconstituted in loading buffer and boiled at 100 °C for 10 min. An equal amount of the protein (20 μg) was separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and were transferred to NC membranes (Millipore, Schwalbach, Germany). .. After blocked with 5% non-fat dried milk in TBS containing 1% Tween-20 for 60 min at room temperature, the membrane was incubated overnight with primary antibodies against phosphor-EGFR (CST, Tyr1068, #3777T), EGFR (AB clonal, #A11351), Article Title: Network pharmacology integrated with experimental validation to explore the therapeutic role and potential mechanism of Epimedium for spinal cord injury Article Snippet: .. Next, the PVDF papers were blocked using skim milk for 1.5 h, then incubated overnight with the primary antibodies against GAPDH (1: 1000, Goodhere), Article Title: Repression of Polycomb Group Factor 1 Inhibits EMT Progression in Colon Cancers Cells via Wnt/β-Catenin and PI3K/Akt/mTOR Signaling Pathway. Article Snippet: .. Skim milk (5%) was used to seal the membrane at room temperature for 1 h, and the primary antibody was diluted at 1:1000 and incubated overnight at 4°C (PCGF1, ab259943, Abcam, RRID: AB_10672187; β-actin, ab8827, Abcam, RRID: AB_2305186; N-cadherin, 22,018–1-AP, proteintech, RRID: AB_2813891; E-cadherin, 20,874–1-AP, proteintech, RRID: AB_10697811; Snail-1, 13,099–1-AP, proteintech, RRID: AB_2191756; mTOR, 2972, Cell Signaling Technology, RRID: AB_330978; phosphor-mTOR [Ser2448], 2971, Cell Signaling Technology, RRID: AB_330970; Akt, 9272, Cell Signaling Technology, RRID: AB_329827; Membrane:Article Title: Design, synthesis and biological evaluation of aminopyrimidine derivatives bearing dihydroquinoxalinone as novel EGFRL858R/T790M kinase inhibitors against non-small-cell lung cancer Article Snippet: After the protein concentrations were determined by a BCA Protein Assay Kit (Thermo Fisher Scientific, Rockford, Illinois, USA), the protein extracts were reconstituted in loading buffer and boiled at 100 °C for 10 min. An equal amount of the protein (20 μg) was separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and were transferred to NC membranes (Millipore, Schwalbach, Germany). .. After blocked with 5% non-fat dried milk in TBS containing 1% Tween-20 for 60 min at room temperature, the membrane was incubated overnight with primary antibodies against phosphor-EGFR (CST, Tyr1068, #3777T), EGFR (AB clonal, #A11351), Article Title: Repression of Polycomb Group Factor 1 Inhibits EMT Progression in Colon Cancers Cells via Wnt/β-Catenin and PI3K/Akt/mTOR Signaling Pathway. Article Snippet: .. Skim milk (5%) was used to seal the membrane at room temperature for 1 h, and the primary antibody was diluted at 1:1000 and incubated overnight at 4°C (PCGF1, ab259943, Abcam, RRID: AB_10672187; β-actin, ab8827, Abcam, RRID: AB_2305186; N-cadherin, 22,018–1-AP, proteintech, RRID: AB_2813891; E-cadherin, 20,874–1-AP, proteintech, RRID: AB_10697811; Snail-1, 13,099–1-AP, proteintech, RRID: AB_2191756; mTOR, 2972, Cell Signaling Technology, RRID: AB_330978; phosphor-mTOR [Ser2448], 2971, Cell Signaling Technology, RRID: AB_330970; Akt, 9272, Cell Signaling Technology, RRID: AB_329827; |
